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Abstract
Degeneration and loss of lower motor neurons is the major pathological hallmark of spinal
muscular atrophy (SMA), resulting from low levels of ubiquitously-expressed survival motor
neuron (SMN) protein. One remarkable, yet unresolved, feature of SMA is that not all motor
neurons are equally affected, with some populations displaying a robust resistance to the
disease. Here, we demonstrate that selective vulnerability of distinct motor neuron pools
arises from fundamental modifications to their basal molecular profiles. Comparative gene
expression profiling of motor neurons innervating the extensor digitorum longus (disease-
resistant), gastrocnemius (intermediate vulnerability), and tibialis anterior (vulnerable) mus-
cles in mice revealed that disease susceptibility correlates strongly with a modified bioener-
getic profile. Targeting of identified bioenergetic pathways by enhancing mitochondrial
biogenesis rescued motor axon defects in SMA zebrafish. Moreover, targeting of a single
bioenergetic protein, phosphoglycerate kinase 1 (Pgk1), was found to modulate motor neu-
ron vulnerability in vivo. Knockdown of pgk1 alone was sufficient to partially mimic the SMA
phenotype in wild-type zebrafish. Conversely, Pgk1 overexpression, or treatment with tera-
zosin (an FDA-approved small molecule that binds and activates Pgk1), rescued motor
axon phenotypes in SMA zebrafish. We conclude that global bioenergetics pathways can be
therapeutically manipulated to ameliorate SMA motor neuron phenotypes in vivo.
Author summary
Selective vulnerability of particular cell types is a prominent, unresolved feature of many
neurodegenerative diseases. In SMA, motor neurons are the most affected cell type, but
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006744 April 20, 2017 1 / 27
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Boyd PJ, Tu W-Y, Shorrock HK, Groen
EJN, Carter RN, Powis RA, et al. (2017)
Bioenergetic status modulates motor neuron
vulnerability and pathogenesis in a zebrafish model
of spinal muscular atrophy. PLoS Genet 13(4):
e1006744. https://doi.org/10.1371/journal.
pgen.1006744
Editor: Gregory A. Cox, The Jackson Laboratory,
UNITED STATES
Received: November 8, 2016
Accepted: April 5, 2017
Published: April 20, 2017
Copyright: © 2017 Boyd et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All gene expression
datasets (.CEL files) are freely available in a public
database (http://www.ncbi.nlm.nih.gov/geo/;
GSE86908). All other relevant data are provided
within the paper and Supporting Information files.
Funding: This study was supported by grant
funding from the UK SMA Research Consortium
(SMA Trust) (to THG and CGB), Muscular
Dystrophy UK (RA2/3040; to THG and CGB),
Wellcome Trust (106098/Z/14/Z; to EJNG and
not all motor neuron pools are affected at the same rate. Some pools degenerate early in
disease and others remain resistant. Understanding the mechanisms governing this selec-
tive vulnerability could identify candidates for protective modifier therapy development.
Using laser capture microdissection and microarray analysis, we show that resistant
motor neuron pools have a different basal bioenergetic profile compared to vulnerable
motor neuron pools. We subsequently showed that defective bioenergetics is a feature in
the pathogenesis of SMA, using both mouse and zebrafish SMA models. We also show
that targeting of bioenergetic genes rescued motor neuron outgrowth defects in a zebra-
fish SMA model. In conclusion, we have identified bioenergetics as a potential protective
modifier. Therapeutic targeting of these pathways could stabilize more vulnerable motor
neurons which could halt or delay disease progression.
Introduction
Spinal Muscular Atrophy (SMA) is an autosomal recessive childhood neuromuscular disorder.
The disease is characterized by muscle weakness and paralysis, resulting from early neuromus-
cular junction (NMJ) breakdown occurring prior to a widespread loss of lower motor neurons
(MN) from the ventral horn of the spinal cord [1]. SMA occurs as a consequence of reduced
levels of the ubiquitously-expressed Survival Motor Neuron (SMN) protein, caused by muta-
tions in the Survival Motor Neuron 1 (SMN1) gene [2]. Complete loss of SMN protein is lethal
to all cells and tissues. However, in humans a nearly identical second copy of the SMN1 gene
exists: SMN2 [3]. Unfortunately, this gene possesses a nucleotide change (C to T) in exon 7
rendering it capable of only producing low levels of full-length SMN protein [4, 5]. SMA is
usually categorized into four distinct clinical subtypes dependent on disease severity (Type I
through to Type IV), where Type I represents the most severe form with death occurring
within the first two years of life. A patient’s copy number of SMN2 determines the subtype and
disease severity, with a higher copy number of SMN2 correlating with the less severe forms of
the condition [6, 7]. The SMN protein has well-established, important cellular roles in the bio-
genesis of small nuclear ribonuclear proteins (snRNP) and pre-mRNA splicing [8–10]. How-
ever, other non-canonical functions for SMN have also been recently identified including:
roles in axonal transport [11, 12], the regulation of ubiquitin homeostasis [13–15] and a contri-
bution to endocytic pathways [16, 17].
Large alpha motor MNs are the most affected cell population in SMA [18], with a break-
down of MN inputs at the NMJ being one of the earliest pathological features of SMA, occur-
ring prior to the onset of overt symptoms and motor neuron loss [19–24]. Given that SMN is
ubiquitously expressed and required by all cells and tissues of the body, it is still unclear why
MNs show a particular vulnerability in SMA [25]. Perhaps even more surprising, it has been
repeatedly demonstrated that a differential sensitivity exists between pools of MNs innervating
distinct muscles. In mouse models of SMA some MN pools have been shown to be readily vul-
nerable to degeneration, showing high levels of NMJ denervation, whereas other MN pools in
the same animal can remain intact throughout the entire course of disease progression, varying
considerably across muscles [21, 26]. This finding supports the hypothesis that a subset of
MNs possesses unique intrinsic characteristics that protect them against degeneration [27].
What these protective properties are, however, remains to be elucidated.
The relative vulnerability of MN pools innervating anatomically distinct muscle targets has
been extensively mapped in SMA mouse models by our own and other laboratories using
NMJ degeneration as a direct readout of vulnerability status [26–28]. Studies of a related
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neurodegenerative condition, Amyotrophic Lateral Sclerosis (ALS) revealed that larger, fast-
fatigable MNs were particularly susceptible, suggesting that morphological properties may be
important contributors to determining selective vulnerability [29–31]. However, in SMA, the
vulnerability spectrum identified across several MN pools was found to be independent from
their core physical features including: position in the body of the innervated muscle, functional
sub-type, nerve stump length, muscle fibre type, motor unit size, branching pattern of the MN
axon, developmental synapse elimination rate, or terminal Schwann cell number [26, 28]. This
strongly suggests that morphological features do not dictate the vulnerability of MN pools in
SMA, and increases the likelihood that differences in the molecular properties of distinct MN
pools are influencing their relative susceptibility [27]. The identification of mechanisms gov-
erning selective vulnerability in SMA has the potential to reveal novel therapeutic targets capa-
ble of directly modulating motor neuron pathology, with potential relevance for other, related
neurodegenerative disorders where selective vulnerability is also present [32, 33].
In the current study, we tested the hypothesis that the molecular composition of resistant
MN pools makes them better placed to deal with the cellular stresses associated with disease
triggers in SMA. We present evidence showing significant differences in the basal transcrip-
tional profile between vulnerable and disease-resistant MN pools in mice, with the most strik-
ing difference being a greater expression of mitochondrial and energy metabolism-related
genes in disease-resistant MNs. Given that MNs are large, highly active cells, with elevated
energy demands to maintain cellular specific functions including the firing of action potentials
at pre-synaptic terminals, it is perhaps not surprising that ATP availability could be important
for their resistance in disease [34]. Furthermore, it was recently shown that vulnerable fast fati-
gable MNs are more affected by milder changes in bioenergetic status than more resistant
MNs suggesting that bioenergetics could be a key determinant of selective vulnerability in
related motor neuron diseases such as amyotrophic lateral sclerosis (ALS) [35]. We therefore
also show that manipulating mitochondrial and glycolytic bioenergetic pathways in smn mor-
phant zebrafish can ameliorate SMA phenotypes, implicating these pathways as potential ther-
apeutic targets.
Results
Comparative gene expression profiling of differentially affected motor
neuron pools reveals modified molecular composition
In order to perform comparative gene expression profiling on pure populations of RNA from
isolated MN pools with known differential susceptibility to SMA, we modified an established
retrograde labelling approach to allow selective isolation of MN pools from the spinal cord.
Wheat Germ Agglutinin (WGA) was injected into anatomically distinct muscle groups, result-
ing in labelling of the innervating MN cell bodies within the spinal cord [36] (Fig 1A). Given
that mRNA is transcribed in the cell body and then subsequently transported either in its
mRNA form or as a translated protein, we reasoned that differences in relative transcript abun-
dance identified in MN cell bodies would reflect molecular changes potentially impacting on
all cellular compartments of the MN.
We labelled MN pools innervating three distinct muscle groups, all located in the hind-
limb of the mouse, which we have previously shown to have differential vulnerability status in
SMA using endplate occupancy as a readout for degeneration in SMA (S1 Fig) [28]. We identi-
fied MN pools projecting to the disease-resistant extensor digitorum longus (EDL) muscle,
intermediate gastrocnemius (GS) muscle, and vulnerable tibialis anterior (TA) muscle [28].
This meant that, as far as possible, any potential confounding factors such as muscle position
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PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006744 April 20, 2017 3 / 27
Fig 1. Microarray analysis of differentially vulnerable motor neuron pools reveals fundamental differences in their
basal molecular composition. (A) Schematic illustration of experimental design (TA, tibialis anterior; EDL, extensor digitorum
longus; GS, gastrocnemius; Vul, vulnerable MNs, Res, resistant MNs; Int, intermediate phenotype MNs). (B) Volcano plots of
differentially expressed transcripts in resistant compared to vulnerable MN pools, intermediate compared to vulnerable MN
pools, and resistant compared to intermediate MN pools. (C) Ratio trending analysis: transcripts that were significantly changed
(p<0.05) between resistant (EDL) and vulnerable (TA) groups with a differential trending value in the intermediate (GS) group
were first identified after which the data set underwent enrichment analysis to reveal enriched biological pathways. Graph shows
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in the body, nerve length, and motor neuron soma location in lumbar spinal cord, were stan-
dardized between groups (Fig 1A).
Comparative gene expression profiling studies were performed in young (post-natal day
14), healthy wild-type mice so to ensure that we were detecting only basal differences in the
molecular composition of MN pools, without any secondary changes due to aging or disease-
related stimuli. Non-toxic WGA was micro-injected into one of the three muscles (EDL, GS or
TA) in each mouse (both hindlegs), using a total of three mice and six muscle injections for
each muscle type. Two days after injection, the spinal cord was dissected and RNA was isolated
from retrogradely labelled pure populations of motor neuron cell bodies using laser capture
microdissection (LCM) prior to transcriptional profiling [37] (Fig 1A).
Initial analyses confirmed significant differences in basal gene expression profiles between
the three distinct MN pools (Fig 1B). In order to identify transcriptional changes directly cor-
relating with the relative disease vulnerability status of a MN pool, a trending analysis was
employed to identify transcripts that differed across all three groups according to their relative
vulnerability. Transcripts differentially expressed between the most resistant group (EDL) and
the most vulnerable group (TA) with a significance threshold of P<0.05 were initially identi-
fied. This primary filter revealed two sets of transcripts: 1) those that were deemed potentially
protective, having higher expression in resistant EDL MN pools compared to vulnerable TA
MN pools, and; 2) those that were deemed as potentially harmful, having higher expression
in vulnerable MNs compared to resistant MNs. These genes were then subjected to a second
filtering step in which transcript expression values were required to trend through the inter-
mediate muscle group (GS), in the appropriate direction of vulnerability. For example, a
transcript with increased expression in the resistant versus the vulnerable group had to addi-
tionally show an expression value in the intermediate (GS) group midway between the vulner-
able (TA) and resistant group (EDL). For example, genes grouped by biological function, such
as mitochondrial electron transport genes in Fig 1C, had to show a trending expression pattern
corresponding the vulnerability of that MN pool. Any genes that did not trend through the
intermediate GS muscle were removed from further analysis.
For subsequent analyses we focused on transcript changes that were higher in resistant
(EDL) compared to the more vulnerable groups, in order to identify potential protective modi-
fiers of the disease. This analysis identified 2,065 individual transcripts whose expression was
higher in resistant (EDL) compared to the more vulnerable MN pools (GS and TA) (Microar-
ray files available at http://www.ncbi.nlm.nih.gov/geo/; GSE86908). Thus, robust differences
are present in the molecular composition of distinct MN pools under basal conditions, with
the potential to directly impact on their response to degeneration-inducing stimuli (e.g. low
levels of SMN protein) in SMA.
Enrichment of mitochondrial/bioenergetic genes and pathways in
disease-resistant motor neurons
To explore the molecular mechanisms through which differences in the basal transcriptional
composition of MNs may influence their vulnerability in SMA, our candidate gene list was
an example of genes in one enriched biological pathway (mitochondrial electron transport chain genes). Note that transcripts
showed highest expression levels in resistant (EDL) neurons, with a decreasing level of expression as the vulnerability status of
the groups increased (GS through to TA). (D) qPCR validation for 3 distinct mitochondrial genes confirming up-regulation in
disease-resistant MN pools (N = 3), Unpaired two tailed student t-test (* P<0.05). (E) Bar chart (mean & s.e.m.) showing a
reduction in ATP in the spinal cord of early and late-symptomatic SMA mice compared to littermate controls using an ATP assay
(N = 3 spinal cords per genotype).
https://doi.org/10.1371/journal.pgen.1006744.g001
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taken forward for bioinformatics analysis using Gene Ontology (http://geneontology.org/) and
DAVID (https://david.ncifcrf.gov/) to identify genetic and biological pathway enrichment.
A significant enrichment of mitochondrial and bioenergetic pathway-related genes was
identified in EDL (disease-resistant) MN pools compared to more vulnerable MN pools
(Table 1). The primary function of mitochondria is to generate ATP from oxidative phosphor-
ylation, efficient ATP generation is particularly critical for highly metabolic tissues including
motor neurons that have high energy demand to support cellular functioning and importantly
synaptic transmission [38–40]. Increased expression of several individual mitochondrial genes
identified by the microarray analyses were therefore independently validated with quantitative
PCR, confirming higher expression in disease-resistant MNs (Fig 1D). These findings were of
particular interest in the context of SMA as recent studies have suggested that mitochondrial
abnormalities in both MNs and skeletal muscle may represent a pathological feature of SMA
[41–45]. Moreover, spinal MNs from SMA patient induced pluripotent stem cells (iPSCs)
revealed reduced mitochondrial number, area and transport [46]. Our analyses revealed an
enrichment of mitochondrial genes particularly associated with oxidative phosphorylation,
cellular respiration and generation of metabolites and energy in the resistant motor neuron
pools, identifying a potential role for ATP-dependent pathways in regulating selective vulnera-
bility of MNs in SMA (Table 1).
Given the association identified between the basal expression levels of ATP-dependent
pathways and the vulnerability of MN pools to SMA, we wanted to confirm that similar ATP-
dependent pathways were activated in response to disease-triggers in SMA. ATP assays were
therefore performed on spinal cords extracted from early and late-symptomatic SMA mice
and littermate controls. Levels of ATP were significantly reduced in SMA spinal cords com-
pared to control both in early and late symptomatic mice suggesting a reduction in ATP pro-
duction capabilities in SMA (Fig 1E). Taken together, these data show that expression levels of
genes involved in mitochondrial/bioenergetics pathways are enriched in disease-resistant MN
pools under basal conditions, with ATP-dependent pathways being adversely affected during
the pathogenesis of SMA. This is particularly interesting given a recent report where SMA
mouse motor neurons were found to have key differences in the expression of mitochondrial
bioenergetic genes compared to controls, suggesting a wider role of bioenergetics in the patho-
genesis of SMA [45].
Table 1. Enrichment analysis of microarray data reveals biological pathways changed between disease-resistant and vulnerable motor neuron
pools.
Gene Ontology Term P-Value (p<0.05) False discovery rate (FDR)
GO:0006091~generation of precursor metabolites and energy 4.47E-30 7.81E-27
GO:0022900~electron transport chain 2.61E-22 4.55E-19
GO:0045333~cellular respiration 1.83E-07 3.20E-04
GO:0005739~mitochondrion 1.74E-41 2.48E-38
GO:0019866~organelle inner membrane 6.41E-35 9.12E-32
GO:0005743~mitochondrial inner membrane 1.11E-33 1.58E-30
GO:0031966~mitochondrial membrane 1.38E-29 1.96E-26
GO:0005740~mitochondrial envelope 1.71E-29 2.43E-26
GO:0044429~mitochondrial part 5.89E-27 8.38E-24
GO:0070469~respiratory chain 6.60E-27 9.39E-24
Enrichment analysis of transcripts differentially expressed between differentially vulnerable motor neuron pools identified higher expression of mitochondrial
and ATP producing genes in more resistant (EDL) pools compared to the intermediate (GS) and vulnerable (TA) groups using DAVID Bioinformatics
resources 6.7 software (https://david.ncifcrf.gov/).
https://doi.org/10.1371/journal.pgen.1006744.t001
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Mitochondrial abnormalities are present in a zebrafish model of SMA
To investigate the potential influence of ATP-dependent bioenergetics on MN pathology in
SMA in vivo, we used an established smn knockdown zebrafish model of SMA using an anti-
sense translation blocking morpholino [47–49]. These smn morphant zebrafish embryos have
a robust MN phenotype (visualized in the Tg(hb9:GFP) line), where caudal primary motor
axons fail to grow out in a defined straight direction into the developing somites and instead
have axons with excessive branching and/or truncation. In severe cases, the motor axon fails to
grow altogether. Reducing Smn protein levels using morpholino, synthetic microRNAs or a
stable mutant line results in the same motor axon outgrowth phenotype identifying specificity
and reproducibility of the phenotype [47, 50, 51].
Levels of ATP synthase subunit alpha (ATP5A), a subunit of mitochondrial membrane
ATP synthase which produces ATP from ADP, was significantly reduced in smn morphant
zebrafish embryos (Fig 2A and 2B). This suggests that mitochondrial ATP biogenesis defects
were occurring in smn morphant zebrafish, similar to those previously identified in mice [45,
46]. Western blotting on pooled injected embryos confirmed the efficiency of the morpholino
knockdown of the smn transcript compared to control embryos (S2 Fig). To investigate
whether mitochondria showed signs of mitochondrial respiratory deficits in SMA zebrafish, a
Seahorse XF analyzer was used to measure oxygen consumption rate (OCR), an indicator of
oxidative phosphorylation and therefore mitochondrial respiration (Fig 2C). A significant
reduction in basal respiration was observed in smn morphants at 24 hpf, where motor axon
phenotypes are first visible, suggesting that the smn morphants were respiring at a significantly
lower level to their age matched controls (Fig 2C and 2D). Addition of oligomycin, to inhibit
the ATP synthase complex of the electron transport chain, can be used to calculate how much
of the oxygen consumption is linked to ATP generation. Addition of oligomycin revealed that
smn morphants have lower ATP linked respiration than control embryos (Fig 2C and 2E). Pro-
ton leak was also significantly reduced in smn morphants (Fig 2C and 2F). These data indicate
that there is mitochondrial ATP generation abnormalities in situations of low Smn in vivo,
supporting previous in vitro findings from mouse primary motor neurons [45].
Increasing mitochondrial biogenesis rescues motor neuron phenotypes
in a zebrafish model of SMA
Using the same model, we modulated ATP-dependent pathways by increasing mitochondrial
biogenesis, thereby replicating the molecular profile of endogenously disease-resistant MNs.
Necdin (NDN), a MAGE family protein expressed in all neuronal cells [52], has recently been
demonstrated to promote neuronal mitochondrial biogenesis [53]. Furthermore, its overex-
pression was previously found to have a neuroprotective effect in dopaminergic neurons
exposed to complex I inhibitors [53]. Overexpression of NDN produced an increase in cyto-
chrome C expression, demonstrating an increase in mitochondrial biogenesis (Fig 3A and 3B)
[54]. We found that enhancing mitochondrial biogenesis by overexpressing NDN in our smn
morphant zebrafish embryos resulted in a significant rescue of axonal outgrowth phenotypes
(Fig 3C). There was a significant increase in the numbers of MNs with normal axonal out-
growth (Fig 3D) and a concomitant significant decrease in the number of motor neurons with
missing or truncated axons (severe axons) (Fig 3D). Injection of a control morpholino did not
result in any axonal outgrowth phenotypes confirming phenotype specificity upon smn knock-
down (S3 Fig). Thus, enhancement of mitochondrial biogenesis (replicating the molecular
profile of disease-resistant motor neurons) was sufficient to ameliorate axonal outgrowth phe-
notypes in smn morphant zebrafish.
Bioenergetic regulation of motor neuron pathology in SMA
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006744 April 20, 2017 7 / 27
Fig 2. Mitochondrial dysfunction occurs in smn morphant zebrafish. (A) Levels of ATP5A protein, a subunit of
mitochondrial membrane ATP synthase, were significantly reduced in smn morphant zebrafish. (B) Levels were quantified
using fluorescent Western blotting and normalized to COXIV loading control (N = 3 per group, batches of 30 pooled
zebrafish embryos per lane). (C) Mitochondrial oxygen consumption rates (OCR) of control and smn morphant 24 hpf
zebrafish analyzed using the Seahorse XF24 analyser showed mitochondrial bioenergetic defects (D) Basal respiration
Bioenergetic regulation of motor neuron pathology in SMA
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Bioenergetic-dependent regulation of motor neuron vulnerability is
mediated by PGK1
Given the identification of bioenergetic pathway gene enrichment in disease-resistant MNs,
and the rescue of motor axon phenotypes in vivo when mitochondrial biogenesis was
was significantly reduced in smn morphants compared to controls. (E) ATP linked respiration was significantly reduced in
smn morphants compared to controls. (F) Mitochondrial proton leak was also reduced in smn morphants compared to
controls. N = 14 per group) Unpaired two-tailed student t-test * P<0.05, ** p<0.01 *** p<0.001.
https://doi.org/10.1371/journal.pgen.1006744.g002
Fig 3. Overexpression of necdin ameliorates the motor axon outgrowth phenotype in smn morphant zebrafish.
(A) Western blotting of cytochrome C, an electron transport chain protein showed an increase in NDN overexpressing
embryos suggesting an increase in mitochondrial biogenesis. (B) Cyt C protein levels were quantified relative to a loading
control. (C) Representative confocal micrographs of motor neuron axons exiting the spinal cord in control (top), smn
morphant (middle) and smn morphant over-expressing Ndn (bottom) Tg(hb9:GFP) zebrafish embryos. Note the presence
of the axonal outgrowth phenotype associated with smn knockdown (arrow heads) is reduced in the Ndn expressing
animals. Scale bars = 50 μM. (D) Bar chart (mean & s.e.m.) showing a significant increase in the number of normal MNs,
and a concomitant significant decrease in the number of severely affected MNs, in co-injected smn MO and Ndn mRNA
embryos compared to single smn MO injected embryos at 30 hpf. Unpaired two-tailed student t-tests; * p<0.05, ** p<0.01
*** p<0.001. N = 20 embryos per experimental group.
https://doi.org/10.1371/journal.pgen.1006744.g003
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increased, we wanted to further explore the mechanisms through which other bioenergetic
pathways are mediating MN vulnerability. We hypothesized that those MNs capable of better
meeting increased energy demands, especially at the NMJ, were more likely to remain stable
during disease progression, for example during energy stress induced by the presence of hyp-
oxia in SMA [55].
Phosphoglycerate kinase 1 (PGK1) was one particular gene of interest in our microarray
dataset, identified as having increased expression in resistant motor neurons (Fig 4A). PGK1 is
a key glycolytic enzyme that catalyzes the conversion of 1,3-diphosphoglycerate to 3-phospho-
glycerate, generating the first molecule of ATP in the glycolytic process. Mutations in PGK1
have been associated with a range of phenotypes in human patients, including severe Central
Nervous System (CNS) defects and muscle fatigue [56, 57]. Furthermore, glycolysis has been
shown to be critical for synaptic function [58], generating local ATP for vesicular recycling
and therefore synaptic transmission, a process which is defective in SMA [22]. Glycolysis at
the NMJ is also required during energy stress, including mitochondrial dysfunction, to meet
acute energy demands at the synapse [58].
Expression of PGK1 in motor neuron cell bodies was confirmed using immunohistochem-
istry on spinal cord sections (Fig 4B). Expression of PGK1 was also found in peripheral axons
in the sciatic nerve, where it colocalised with neurofilament proteins but not the glial cell
marker S100 (Fig 4C), suggesting that PGK1 is present throughout the extensive cytoplasm of
MNs in vivo. To confirm additional distal localization of PGK1, immunohistochemistry was
carried out in both cultured mouse cortical neurons and primary motor neurons, confirming
robust expression throughout the axon (Fig 4D and 4F) and at neuronal terminals (Fig 4E and
4G arrows) in both cell types. Co-staining with GAPDH in primary MNs also revealed staining
in both axons and growth cones, suggesting that PGK1 expression in distal compartments is
due to its glycolytic roles in generating local ATP (S5 Fig).
To further explore the potential contribution of PGK1 to SMA disease pathogenesis, we
next examined PGK1 levels in different tissues from late-symptomatic SMA mice (Fig 5A).
PGK1 levels were significantly reduced in SMA mouse spinal cord and sciatic nerve (Fig 5B).
In contrast, PGK1 levels were not significantly changed in skeletal muscle (Fig 5B). We also
observed a reduction of PGK1 in the heart of SMA mice, another highly metabolic tissue and
affected tissue in severe SMA, suggesting that other tissues with high energy requirements may
be affected. This identifies a potential role for energy demand in modulating disease response
and vulnerability across a range of tissues (Fig 5A and 5B). Similarly, a significantly reduced
level of PGK1 in the spinal cord was also observed at an early-symptomatic time point in SMA
mice compared to controls (S6 Fig).
Next, to establish any potential role for PGK1 in modulating motor neuron stability, we
examined the consequence of reducing PGK1 levels on healthy MNs in vivo. Knockdown of
pgk1 in wild-type zebrafish embryos using a morpholino was sufficient to induce an SMA-like
axonal outgrowth phenotype, characterized by greater numbers of truncated motor axons and
abnormal axon branching in pgk1 morphant embryos compared to controls (Fig 5C and 5D).
Efficiency of Pgk1 knockdown in zebrafish embryos was determined by western blot, confirm-
ing that protein levels were reduced by 50% (Fig 5E). The concentration of injected pgk1 mor-
pholino resulted in a dose dependent increase in severe motor axons suggesting specificity of
the phenotype (S7 Fig). Thus, experimental suppression of Pgk1 levels was sufficient to desta-
bilise MNs in vivo, consistent with higher basal levels of Pgk1 conferring protection and stabil-
ity in disease-resistant MNs.
Finally, we wanted to establish whether therapeutic targeting of Pgk1 would be sufficient to
confer a disease-resistant phenotype on MNs in smn morphant zebrafish. We initially used a
genetic over-expression approach to increase Pgk1 levels in smn knockdown zebrafish.
Bioenergetic regulation of motor neuron pathology in SMA
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Fig 4. PGK1 is enriched in disease-resistant motor neuron pools, expressed in neuronal cells cellular and axonal
compartments in vivo and in vitro. (A) Gene expression profile graph showing transcripts trending across differentially
vulnerable motor neuron pools, with PGK1 highlighted. Note that Pgk1 was 5-fold higher expressed in the EDL disease-
resistant motor neuron pool compared to the TA vulnerable motor neuron pool, with expression levels trending through the GS
intermediate pool. (B) Representative confocal micrographs showing expression of PGK1 in the cytoplasm of motor neurons
Bioenergetic regulation of motor neuron pathology in SMA
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Overexpression of pgk1 mRNA in smn morphant zebrafish resulted in a significant rescue of
the axonal outgrowth phenotype (Fig 6A arrows), with fewer MN axons displaying a truncated
outgrowth phenotype and greater numbers of normal MNs (Fig 6B).
To confirm these findings and establish whether this pathway is amenable to more thera-
peutically-relevant (pharmacological) targeting strategies, we repeated our SMA zebrafish
experiments using an FDA-approved small molecule, terazosin (TZ). TZ binds Pgk1 and acti-
vates its enzymatic activity [59], with previous studies revealing a potential for conferring neu-
roprotection in animal models of sepsis and stroke [59]. Activation of Pgk1 using 2.5 μM of
TZ significantly rescued the MN axonal outgrowth phenotypes in smn morphant zebrafish
(Fig 6C and 6D). No morphological or developmental defects were observed with TZ treat-
ments, suggesting no off-target effects (S8 Fig). Thus, targeting of Pgk1, either genetically or
using a small molecule approach, can protect motor neurons from SMA-induced pathology in
vivo. The similar findings obtained between our genetic and pharmacological experiments also
suggest that the effects of terazosin were resulting directly from targeting pgk1, rather than
additional, off-target, effects.
Discussion
Differential vulnerability of MN pools within an individual is a significant feature of the patho-
genesis of SMA. Here, we demonstrate that differences in the basal molecular composition of
MN pools correlate directly with their relative vulnerability or resistance during disease. Gene
expression profiling of three anatomically-distinct MN pools with differing vulnerability in
SMA revealed that disease-resistant MNs had higher basal expression of genes associated with
bioenergetics pathways, which were subsequently found to be perturbed in SMA. Targeting of
these identified bioenergetic pathways, initially by enhancing global mitochondrial biogenesis,
was found to rescue MN defects in smn morphant zebrafish. Similarly, focused targeting of
non-mitochondrial bioenergetic pathways, by increasing the levels or activity of phosphoglyc-
erate kinase 1 (Pgk1), was found to rescue MN phenotypes associated with smn knockdown.
Several studies investigating the underlying factors influencing selective vulnerability of
MNs have been conducted, highlighting it as a keen area of interest in the field of motor neu-
ron disease research. Taken together with our current findings, these suggest that the discovery
of inherent protective modifiers could be fundamental to the development of future successful
combinatorial therapies [33, 60–63]. It is of particular interest to note that mitochondrial path-
ways have been previously highlighted as a potential disease modifier in ALS [64]. Taken
together with our current findings from SMA, this suggests that differences in basal bioener-
getic function could be a fundamental and conserved determinant of MN vulnerability across
a range of different neurodegenerative conditions. Indeed, mitochondrial dysfunction has
been highlighted as an important feature across a broad spectrum of neurodegenerative disor-
ders [40, 65], unsurprising given their extensive roles in cellular homeostasis [38], critically
ATP generation, particularly in neurons [66]. Moreover, it has recently been reported that
treating an ALS mutant mouse model with Triheptanoin to aid ATP generation through
(MN) in mouse spinal cord. Scale bars = 20 μM. (C) Expression of PGK1 was also detected in the majority of axons in the
sciatic nerve (SN), being localised alongside neurofilament (H-NF; upper panels) but not co-localising with glial S100 label
(lower panels). Scale bars = 5 μM (D) In vitro analysis showed expression of PGK1 in the cell body and axonal processes of
mouse cortical neurons (CtxN). Scale bars = 30 μM. (E) Expression of pgk1 was detected in the axonal nerve terminals of
mouse cortical neurons (CtxN). Scale bars = 15 μM. (F) Expression of PGK1 was also found in mouse primary motor neuron
(MN) cell bodies and axonal compartments (arrow). Scale bars = 30 μM. (G) Expression of Pgk1 in the axonal terminals/
growth cones (arrow) of mouse primary motor neurons (MN). Scale bars = 15 μM.
https://doi.org/10.1371/journal.pgen.1006744.g004
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improving oxidative phosphorylation protected motor neurons [67], again suggesting that
therapeutic targeting of ATP production could be beneficial.
From the SMA perspective, our findings add significant additional weight to a growing
body of evidence suggesting that mitochondria are likely to be a critical mediator of disease
pathogenesis. For example, a recent study using RNA sequencing to compare healthy and
Fig 5. Pgk1 expression is pathologically relevant in mouse and zebrafish models of SMA. (A) Expression of PGK1
protein in the spinal cord, skeletal muscle, sciatic nerve and heart of late-symptomatic P8 SMA mice. Protein levels were
quantified and normalized to an appropriate loading control. (B) Bar chart (mean & s.e.m.) showing a significant reduction
in PGK1 protein levels in SMA mouse spinal cord and sciatic nerve. N = 6 SPC per genotype. N = 3 muscle per genotype.
N = 7 sciatic nerves per genotype. N = 3 hearts per genotype (C) Knockdown of Pgk1 in zebrafish induced an axonal
outgrowth phenotype (middle panel arrow) similar to smn knockdown (arrow bottom panel) and also produced swellings in
the tips of outgrowing axons indicative of axonal transport deficiencies. Scale bars = 50 μM (D) Quantification of axonal
outgrowths showed a significant increase in truncated motor axons in pgk1 and smn morphants compared to controls. (E)
Efficiency of pgk1 knockdown in embryos was shown by western blot embryos normalized to an appropriate loading
control (N = 3 per group, batches of 30 pooled zebrafish embryos per lane). N = 20 embryos per group. Unpaired two-
tailed students t-test * p<0.05, ** p<0.01 *** p<0.001 **** p<0.0001.
https://doi.org/10.1371/journal.pgen.1006744.g005
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SMA MNs in vitro identified differential expression levels of several mitochondrial and bioe-
nergetic genes. Furthermore, they confirmed that in SMA MNs, mitochondrial ATP respira-
tion and mitochondrial transport were both reduced [45]. We show similarly here in vivo that
smn morphant zebrafish have reduced ATP linked mitochondrial respiration (Fig 2). Taken
Fig 6. Overexpression or pharmacological activation of pgk1 rescues motor neuron phenotypes in
smn morphant zebrafish. (A) Representative confocal micrographs of primary motor neuron axons exiting the
spinal cord in control (top), smn morphant (middle) and smn morphant over-expressing pgk1 (bottom) Tg(hb9:
GFP) zebrafish embryos. Note the presence of an axonal outgrowth/branching phenotype associated with smn
knockdown (arrow heads) that is reduced in the pgk1 over-expressing animals. Scale bars = 50 μM. (B)
Overexpression of Pgk1 in smn morphant zebrafish at 30 hpf led to a significant increase in normal motor axons
and significant decrease in severe axonal outgrowth phenotypes compared to single smn MO injected
embryos. (C) Representative confocal micrographs of motor neuron axons exiting the spinal cord in control
(top), smn morphant (middle) and smn morphant treated with 2.5 μM terazosin (bottom) Tg(hb9:GFP) zebrafish
embryos. Note how the presence of the axonal outgrowth/branching phenotype associated with smn
knockdown (arrow heads) is reduced in the terazosin-treated animals. (D) Bar chart (mean & s.e.m) showing
activation of Pgk1 by treatment with 2.5 μM terazosin in smn morphant zebrafish at 30 hpf led to a significant
increase in normal motor axons and significant decrease in severe axonal outgrowth phenotypes compared to
untreated smn MO injected embryos. Unpaired two-tailed student t-tests * p<0.05, ** p<0.01 *** p<0.001.
n = 20 embryos per group.
https://doi.org/10.1371/journal.pgen.1006744.g006
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together with our finding that targeting of bioenergetic pathways rescues MN defects in smn
morphant zebrafish, this suggests that MNs with a greater bioenergetic capacity have higher
disease resistance due to greater energy supply for critical MN functions (Fig 7).
During hypoxia or mitochondrial dysfunction, cells become more reliant on glycolysis to
produce ATP to meet acute energy demands. Both mitochondria and glycolysis are responsible
for generating the majority of cellular ATP. Mitochondria and glycolytic machinery are both
present at neuronal synapses providing energy for synaptic transmission and vesicular recy-
cling [68], with enrichment of glycolytic machinery found at neuronal terminals providing
local ATP when under high energy demands or in smaller synapses where mitochondria are
absent [58]. As synapses are known to be particularly susceptible in SMA, it is interesting to
note that we have previously found glycolytic proteins to be altered in synapses from SMA
mouse brain [13]. Moreover, given that defects in vasculature lead to hypoxic conditions
(causing reduced oxygen availability for mitochondrial oxidative phosphorylation) throughout
the neuromuscular system in SMA [55, 69], it is likely that those cells more capable of meeting
energy demands by alternative methods may be more resistant to the disease.
This contribution of glycolytic pathways to neuronal and synaptic health is consistent with
our finding that Pgk1, a key glycolytic gene, showed a 5-fold enrichment in disease-resistant
MNs (EDL). Mutations in PGK1 present with a wide range of clinical manifestations in human
patients, including CNS defects and muscle defects (both tissues with high metabolic demands
that are also affected in SMA) [56, 57]. We confirmed robust expression of PGK1 in the cyto-
plasm of MNs and at axon terminals, suggesting that it is an important contributor to bioener-
getic pathways in this cell type (Fig 4). Moreover, reducing levels of pgk1 in wild-type zebrafish
Fig 7. Summary model showing ATP-generating pathways likely to influence the vulnerability status of MNs in SMA. Efficient ATP generation
through different processes maintains levels in energy demanding MNs, critical for their function and survival during disease. Certain motor neuron pools
possess inherently higher bioenergetic capacities that provide protection during cellular insult both at the cell body and at the NMJ. Efficient ATP
generated from mitochondria allows cellular homeostasis to be maintained. During hypoxia, glycolytic pathways are employed to meet acute ATP
demand, particularly at the NMJ, critical for vesicular recycling and synaptic transmission. Mitochondrial transport along the axon provides local ATP to
maintain axonal integrity. Glycolytic machinery present along the axon allows for fast vesicular transport down to the NMJ to deliver packaged proteins for
pre-synaptic function.
https://doi.org/10.1371/journal.pgen.1006744.g007
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resulted in an smn morphant axonal outgrowth phenotype, confirming a direct influence on
the regulation of MN stability and health (Fig 5C and 5D).
Previous studies using FDA approved terazosin (TZ), which activates PGK1, revealed pro-
tective effects in both stroke and sepsis models, most likely due to enhanced stress resistance
[70], in keeping with our findings from SMA models. Moreover, other studies have suggested
that its protective function may be additionally mediated by effects on the glycolytic machinery
and its regulation of fast synaptic vesicular transport along axons, required to provide local
ATP at synaptic terminals [68, 70]. Whether PGK1 is protective due to increased vesicle trans-
port in disease resistant motor neurons remains speculative, but it could be highly relevant in
SMA given that axonal transport and ATP related deficiencies have been actively implicated in
disease pathogenesis [11, 45, 71–73].
Importantly, our finding that elevation of Pgk1 levels or activity, via injection of Pgk1
mRNA or treatment with terazosin respectively, robustly ameliorated MN pathology in smn
morphant zebrafish provides an initial demonstration that these pathways are amenable to
therapeutic intervention. Moreover, the fact that inherently ‘disease-resistant’ MNs already
have higher levels of PGK1 would suggest that elevating levels across all neurons (albeit whilst
remaining within physiological levels) would be a safe therapeutic intervention. Encourag-
ingly, our terazosin experiments also suggest that there are existing FDA-approved drugs that
can activate PGK1 enzymatic activity that may be suitable for repurposing for conditions such
as SMA. As SMN-targeted therapies progress through clinical trials, showing promise to mod-
ify disease but likely falling considerably short of offering a ‘cure’ for SMA [74], it is becoming
clear that additional, complementary therapies are going to be required [17]. Our findings sug-
gest that targeting the bioenergetic status of MNs represent one attractive approach to develop
such a combinatorial therapy. Finally, given that other highly metabolic tissues are affected in
SMA patients and animal models, bioenergetic therapies could also be beneficial for non-MN
pathology associated with the disease [25].
Materials and methods
Animals
Wild-type FVB mice (both male and female) at P14 were used for microarray experiments.
The Taiwanese mouse model of severe SMA (Smn-/-; SMN2tg/o) on a congenic FVB back-
ground was used for SMA experiments [75], employing a breeding strategy previously
described [76]. Age matched, phenotypically normal littermate (Smn+/-; SMN2tg/o) mice were
used as controls, with all animals being retrospectively genotyped using standard PCR proto-
cols [76]. Mouse breeding stocks were originally obtained from Jackson laboratories and were
maintained in animal care facilities at the University of Edinburgh under standard specific
pathogen free conditions. Zebrafish embryos were maintained using standard protocols at
28.5˚C and staged by hours post-fertilization (hpf) [77]. Adult wildtype and Tg(hb9:GFP) zeb-
rafish [78] were maintained in a fish facility at the University of Edinburgh according to stan-
dard methods.
Synaptic vulnerability analysis and quantification
Muscles were dissected, processed and imaged as previously described [28]. In short at least 80
endplates per muscle per mouse were assessed in each muscle preparation in wildtype and
SMA mice. For endplate occupancy counts, the occupancy of NMJs was determined by classi-
fying endplates as either fully occupied (neurofilament and SV2 entirely overlie the endplate),
partially occupied (neurofilament and SV2 cover less than 50% of the endplate), or vacant (no
neurofilament or SV2 overlying the endplate).
Bioenergetic regulation of motor neuron pathology in SMA
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006744 April 20, 2017 16 / 27
Retrograde labelling and tissue preparation for LCM
Nine FVB mice from the same wild-type FVB litter at p14 were divided into three groups
according to the muscle location being injected, resulting in groups of 3 mice per muscle. Mice
were anaesthetized and a small surgical incision was made in the skin of the hindleg. 20μg/ml
of WGA-HRP (Vector Laboratories; PL-1026)) was injected into individual tibialis anterior
(TA, vulnerable; 3μl), gastrocnemius (GS, intermediate; 3μl), and extensor digitorum longus
(EDL, resistant; 1μl) muscles. Mice were sacrificed and perfused with PBS 48 hours after sur-
gery. Spinal cords were immediately collected, embedded in optimal cutting temperature com-
pound (OCT) and stored at -80˚C. In order to minimise contamination from other cell types
when performing laser capture microdissection, frozen sections (35 μm) were mounted onto
PEN-membrane slides (Applied Biosystems, Foster City, CA). Tissue sections were fixed in
cold acetone and then dehydrated using a cold graded ethanol series (75%, 95% and 100% for
30 seconds), and xylene for 3 min. Dehydrated sections were developed with NovaRED Perox-
idase (HRP) Substrate (Vector Laboratories, Burlingame, CA) for 3 min. Those sections identi-
fied positively for retrograde labelling were then transferred to the Arcturus Veritas laser
capture microdissection system (Applied Biosystems) for isolation of labelled MN soma.
RNA isolation, amplification and microarray hybridization
Total RNA was extracted from isolated MNs using PicoPure RNA Extraction kit according to
the manufacturer’s instructions (Applied Biosystems). Approximately 100 ng of total RNA was
obtained from labelled MNs extracted from a single spinal cord using LCM. Before hybridisa-
tion, samples were subjected to linear amplification, and the products were analysed for quality
(Agilent 2100 Bioanalyzer, RNA 6000 NanoChip) and quantity (NanoDrop 1000 Spectropho-
tometer) according to the GeneChip Pico Kit protocol (Affymetrix). In brief, the 100ng of total
RNA was amplified with random primers containing a T7 polymerase promoter site. At the end
of reactions, double-stranded cDNA was generated ready for in vitro transcription to synthesise
copy RNA (cRNA). The cRNA (20 μg) was subsequently used as template for generating single-
stranded cDNA (ss-cDNA), afterwhich 5.5μg of fragmented and biotin-labelled ss-cDNA was
hybridised to one GeneChip Mouse Transcriptome Assay 1.0 (Affymetrix) for 16hr at 45˚C, fol-
lowed by stringent washing in a GeneChip Fluidics Station 400 (Affymetrix) and scanning using
a GeneChip Scanner 30007G (Affymetrix). Datasets (.CEL files) taken forward for further analy-
sis are freely available in the public database (http://www.ncbi.nlm.nih.gov/geo/; GSE86908).
Microarray analysis
The.CEL files were processed using an Affymetrix Expression Console with the sst-RMA sum-
marisation algorithm. To identify transcript changes correlating to susceptibility, statistically
significant differences were determined by comparing three subtypes of differentially affected
motor neuron pools (tri-wise or 3-way comparison) in Transcription Analysis Console 3.0
(Affymetrix). The variable gene list was then generated based on two cut-offs: 1) genes signifi-
cantly different between EDL (resistant) and TA (vulnerable) groups, and 2) gene expressions
fitting a trend either increasingly or decreasingly through EDL (resistant)-GS (intermediate)-
TA (vulnerable). Gene Ontology (http://geneontology.org/) and DAVID (https://david.ncifcrf.
gov/) were used to identify genetic and biological pathway enrichment in the data set.
Quantitative RT-PCR
A proportion of the RNA amplified from laser-captured EDL and TA motor neurons was used
in quantitative PCR to verify expression levels of 3 distinct mitochondrial genes, Ndufa1,
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Uqcrq and Cox5a. cDNA was synthesised using qScript cDNA synthesis kit according to the
manufacturer’s protocol (Quanta). qPCR was performed using 12.5 ng cDNA, 1X SensiFast
SYBR (Bioline) and optimised primers (Table 2), to a total volume of 20 μl. After the initial
denaturation at 95˚C for 2 min, cDNA was amplified by 40 cycles of 95˚C for 5 sec and 63˚C
for 25 sec, on a CFX96 Real-Time PCR system (Bio-Rad). Gene expression levels were normal-
ised to β-actin expression and ΔΔCt calculation was applied to generate relative concentration.
The statistical analysis was performed using a two-tailed unpaired t test.
ATP assay
Spinal cords from early-symptomatic p5 and p8 late-symptomatic SMA mice and control mice
were dissected and pooled by genotype to produce a total of 20mg of tissue. Spinal cords were
homogenised and deproteinized using Perchorlic acid (PCA). Samples were then measured
for ATP concentrations using the Abcam ATP assay kit, following manufacturer’s instructions
(ab83355, Abcam).
Zebrafish protein preparation
Wildtype AB stain one cell stage embryos were injected with 6ng of MO and left to develop
until 48 hpf. Embryos were dechorionated and deyolked in 1ml of deyolking buffer (1/2 Ginz-
burg Fish Ringer without Calcium: 55 mM NaCl, 1.8 mM KCL, 1.25 mM NaHCO3). Embryos
were pooled into batches of 30 embryos, with three replicate batches per experimental group.
Embryos were pelleted at 300g for 30 seconds and the supernatant was discarded. Embryos
were washed twice with wash buffer (110mM NaCL, 3.5 mM KCl, 2.7 mM CaCl2, 10 mM Tris
pH 8.5) and cells pelleted at 300g for 30 seconds. The supernatant was removed and cellular
pellet was stored at -80˚C until use [79].
Quantitative fluorescent western blotting
All protein (zebrafish embryos and mouse tissue) was extracted in RIPA buffer (ThermoScien-
tific) with 1% protease inhibitor cocktail (Sigma) and homogenised. Protein concentration
was determined by BCA assay (ThermoScientific). SDS-page was performed using 20% pre-
cast NuPage 4–12% BisTris gradient gels (Life Technologies) and transferred to PVDF mem-
branes by the iBlot 7 minute semi-dry blotting system (Life Technologies). Following blocking,
membranes were incubated overnight at 4˚C using mouse anti-SMN (1:1,000, BD biosciences,
610153), rabbit anti-PGK1 (1:1000, Millipore, ABS787), rabbit anti-ATP5A (1:1000 ab176569,
Abcam), rabbit anti-cyt C (1:1000, Abcam, ab18738) mouse anti-COX IV (1:1000 Abcam,
ab14744), mouse anti- GAPDH (1:1000, Abcam, ab9484,). After PBS washes, secondary anti-
bodies were added for 1 hour at room temperature. Secondary antibodies used were; IR dye
800CW goat anti-mouse IgG (926–32210), IR dye 800CW goat anti-rabbit IgG (926–3211), IR
dye 680RD goat anti-mouse IgG (926–68070), IR dye 680RD goat anti-rabbit IgG (926–
68071), all 1:5,000, LI-COR Biosciences. Membranes were imaged using an odyssey infrared
imaging system (Li-COR, Biosciences) as described previously [80], and quantified using an
Table 2. Primer sequences used in quantitative PCR.
Gene symbol Primer sequences Conc. Efficiency
Ndufa1 F, 5’GAGTAACGGTGCGGAGATGT3’ R, 5’CGTTGGTGAATTTGTGGATG3’ 100nM 100%
Uqcrq F, 5’GTCTACCTGATCTACACATGGG3’ R, 5’CAGAGAAGGGTCTTTCAGAGG3’ 250nM 100%
Cox5a F, 5’GCCGCTGTCTGTTCCATTC3’ R, 5’GCATCAATGTCTGGCTTGTTGAA3’ 100nM 94%
https://doi.org/10.1371/journal.pgen.1006744.t002
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image studio software (Li-COR). To determine final relative protein expression, band intensi-
ties were normalized to a loading control or a ponceau stain.
Morpholino knockdown in zebrafish
Previously published smn morpholino was designed against the 5’ start sequence of the smn
gene (Gene Tools LLC); 5’ CGACATCTTCTGCACCATTGGC ‘3.
An antisense MO was designed against the translational start codon of the pgk1 gene (Gene
Tools LLC): 5’ TCGAAAGAGACATTTTGCCTGTGGT ‘3.
A control MO from gene tools was also used to confirm specificity of the motor axon phe-
notype (Gene Tools LLC).
Knockdown efficiency was quantified using western blot analysis, and normalized against a
loading control.
Oxygen consumption rate for the determination of respiratory function
Zebrafish embryos were injected with smn MO at the one cell stage and left to develop until 24
hpf. Oxygen consumption rate (OCR) was measured from embryos using a V17 Islet capture
plate in the Seahorse Bioanalyser XFe24 (Agilent). System water was used as the media for
wells, and for the preparation of drugs for injection during the run, two dechorinated embryos
were placed in each well. All measurement cycles for the run were set to 2 minute mix, 90 sec-
ond wait, and 3 minute measure. Prior to any drug administration 6 ‘basal’ measurements
were taken, oligomycin was then added followed by 3 measurement cycles. FCCP was then
added followed by another 3 measurement cycles. Finally, a mixture of antimycin and rote-
none were added followed by 10 measurement cycles. Optimal doses of drugs were optimised
separately for control and smn morphant embryo’s. Final concentrations of drugs were as fol-
lows; control oligomycin 50–75 μM, smn morphant oligomycin 25μM, control FCCP 20 μM,
smn morphant FCCP 3μM. Antimycin and rotenone were added to a final concentration of
2uM for both control and smn morphants. To calculate basal respiration from each well, the
last OCR measurement following the addition of antimycin and rotenone was subtracted from
the 6th basal OCR measurement. ATP linked (oligomycin sensitive) respiration was calculated
by subtracting the lowest of the 3 OCR measurements following the addition of oligomycin,
from the 6th basal OCR measurement. Proton leak respiration was calculated by subtracting
the last OCR measurement following the addition of antimycin and rotenone from the lowest
OCR measurement following oligomycin. Maximal respiration was calculated by subtracting
the last OCR measurement following the addition of antimycin and rotenone from the highest
OCR measurement following FCCP. Spare respiratory capacity was calculated by subtracting
the 6th basal OCR measurement from the highest OCR measurement following FCCP. Any
well, that after calculation gave rise to a negative value for their ATP linked respiration, was
excluded from the analysis. One well from the control, and one well from the smn morphant
group were excluded from this data by this criterion.
Construct generation and in vitro transcription reaction
Overexpression constructs were generated from cDNA and ligated into an PCS2+MT expres-
sion vector. Zebrafish full-length Pgk1 was ligated using the bamH1 restriction sites. Mouse
full-length Necdin was ligated using xho1 and xba1 sites. Vectors were linearized and an in
vitro transcription reaction performed using the SP6 promoter using the mMessage mMachine
kit (AM1340, Ambion).
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Zebrafish rescue experiments
Single cell stage Tg(hb9:GFP) embryos were injected with 4ng smn MO in aqueous solution
containing 0.05% phenol red or 4ng smn MO co-injected 200 ng/μl full length zebrafish pgk1
or full length mouse 300 ng/μl necdin mRNA in aqueous solution and left to develop until 30
hpf for evaluation of motor axon phenotype.
Zebrafish drug experiments
Single cell stage Tg(hb9:GFP) embryos were injected with 4ng smn MO in aqueous solution
containing 0.05% phenol red and left to develop until 6 hpf before treatment with 2.5 μM tera-
zosin, dissolved in water (Sigma-Aldrich) with untreated smn morphants were kept as con-
trols. Embryos were retreated at 24 hpf with 2.5 μM terazosin and fixed at 30 hpf for
evaluation of motor axon phenotype.
Motor axon phenotype evaluation
For immunostaining, treated Tg(hb9:GFP) embryos were dechorinated at 30 hpf and fixed in
4% PFA overnight before being dehydrated in 100% methanol. Embryos were rehydrated and
washed in PBS before being transferred into 100% acetone for 10 minutes at -20˚C for permea-
bilisation. Embryos were washed in PBST (PBS, 1% DMSO, 1% BSA and 0.5% triton-X 100)
before being blocked in PBST plus 2% Sheep serum, followed by overnight incubation of
chicken anti-GFP primary antibody (1:1,000, Abcam, ab13970). Embryos were washed in
PBST and then incubated in Alexa Flour 488 secondary antibody (1:500) (Jackson 703-545-
155). Embryos were mounted in 80% glycerol and a z stack was imaged using a Zeiss LSMZ10
confocal microscope. The percentage of motor neurons with normal axonal outgrowth,
branched axonal outgrowth and severe truncated axons was then analysed as previously
described [47] (N = 20 embryos per treatment group, 12 axons per embryo (6 segments) ana-
lysed behind the yolk and shown as a percentage). The observer was blinded to the treatment.
Immunohistochemistry
Tissue from mice was dissected and fixed in 4% paraformaldehyde in PBS for 4 hours for spi-
nal cords, and 1 hour for sciatic nerves at 4˚C before being transferred into 30% sucrose solu-
tion over-night at 4˚C for cryoprotection. Tissue was embedded in OCT (1:1 OCT and 30%
sucrose for sciatic nerve) and using a cryostat, where spinal cord (25 μM) and sciatic nerve
(10 μM) sections were collected on polysine-coated slides (Thermo Scientific). For immuno-
histochemistry, sections were permeabilized in 0.3% Triton X-100 in PBS and then blocked
(4% BSA, 0.3% Triton X-100 in PBS) for 30 minutes at room temperature before overnight
incubation with primary antibody solution at 4˚C: anti-PGK1 (Millipore, ABS787) and mouse
anti-S100 (Abcam, AB7852) or mouse anti-NF heavily phosphorylated 200 (convence, SMI-
31R). After PBS washes, sections were incubated with secondary antibody solution for 2 hours
at room temperature: Alexa Fluor 488 donkey anti-rabbit IgG (1:500, Life Technologies, A-
21206), Alexa Fluor 594 donkey anti-mouse IgG (1:500, Life Technologies A21203). Sections
were counterstained with DAPI nuclei stain (1:1,000, Life Technologies, D1306) for 10 min-
utes before being mounted with 10% Mowiol (Polysciences). Images were taken using a Zeiss
LSMZ10 confocal microscope.
Primary neuron culture and immunocytochemistry
Primary cortical neurons and primary motor neurons were cultured as previously described
[81, 82]. Briefly, timed-mated mice were sacrificed by cervical dislocation at embryonic day 13
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(E13, motor neurons) or E14 (cortical neurons). For motor neurons, the ventral spinal cord
was dissected, incubated in 0.05% trypsin for 15 min at 37˚C and dissociated by pipetting. A
motor neuron fraction was obtained by centrifugation for 15 min at 685 x g of the dissociated
cells on a 6% optiprep gradient column. Motor neurons were pelleted by centrifugation for 10
minutes at 170 x g on a 4% BSA cushion and plated in glia-conditioned medium (neurobasal
medium with B27 and glutamax, incubated on mixed primary glia for 24 hours) containing
5% normal horse serum and BDNF, CNTF and GDNF at 10 ng/mL. Cultures of mixed pri-
mary cortical neurons were obtained by incubating dissected embryonic cortices in 0.25%
trypsin for 10 minutes at 37˚C and dissociating them using a flame-polished glass pipette. Cor-
tical neurons were seeded at 40,000 per well and motor neurons at 10,000 per well on cover-
slips coated with poly-D-lysine (cortical neurons) or poly-D,L-ornithine (motor neurons) and
laminin. For immunohistochemistry primary cortical neurons and primary motor neurons
were fixed at day 7 in 4% PFA (Electron Microscopy Sciences) with 4% sucrose for 10 minutes,
permeabilised in 0.1% Triton X-100 (Sigma) for 5 minutes, washed twice in PBS and blocked
in PBS containing 2.5% BSA for 30 minutes. They were subsequently incubated with anti-
PGK1 (ABS787, Millipore) and mouse beta III tubulin (T8860, Sigma) in 2.5% BSA for 1
hour at RT. After 3 washes in PBS cells were incubated with Alexa Fluor 488 donkey anti-rab-
bit IgG (1:500, Life Technologies, A-21206) and Alexa Fluor 594 donkey anti-mouse IgG
(1:500, Life Technologies A21203) for one hour. Cells were counterstained with DAPI nuclei
stain (1:1,000, Life Technologies, D1306) before being mounted with 10% Mowiol.
Statistical analysis
Data were collected and analysed using Microsoft Excel and GraphPad Prism 6 software.
Individual statistical tests are described in the main text and figure legends. For all analysis,
P 0.05 was considered statistically significant. All data are expressed as mean ± SEM. For all
figures; NS P> 0.05,  P 0.05,  P 0.01,  P 0.005,  P 0.001.
Study approval
All experimental procedures involving animals were conducted in accordance with United
Kingdom Home Office regulations, were approved by a University of Edinburgh internal eth-
ics committee and local veterinary staff, and were performed under license from the UK
Home Office (PPL 60/4569).
Supporting information
S1 Fig. Representative images of NMJ pathology in EDL, GS, and TA muscles. (A) Images
of NMJs from three differentially vulnerable hindleg muscles in SMA mice, arrows show
examples of partially or unoccupied endplates in vulnerable GS and TA muscles. (B) Quantifi-
cation of fully occupied endplates, note the EDL muscle remained resistant throughout SMA
disease progression with a high percentage of fully occupied endplates. In contrast the GS and
TA muscle showed a loss of fully occupied endplates in SMA, with an increase in partially or
unoccupied endplates. The TA muscle showed the largest reduction in fully occupied end-
plates with less than 50% at p5 in the SMA mice. Bar chart mean and s.e.m.
(TIF)
S2 Fig. Quantification of axonal outgrowth in control MO injected embryos. (A) Represen-
tative confocal micrographs of primary motor neuron axons exiting the spinal cord in un-
injected control (top) and control MO (bottom) in 28 hpf Tg(hb9:GFP) embryos. (B) Injection
of a control MO at 1mM did not lead to any motor axon phenotypes, and showed the same
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number of normal motor axons as the un-injected controls. Bar chart (mean & s.e.m).
Unpaired two-tailed student t-test. NS- not significant.
(TIF)
S3 Fig. Knockdown of Smn via morpholino efficiency. (A) Efficiency of Smn knockdown as
determined by western blot in 48hpf zebrafish. (B) knockdown was quantified and normalized
to CoxIV loading control (N = 3 per group, batches of 30 pooled zebrafish embryos per lane).
Bar chart (mean & s.e.m). Unpaired two-tailed student t-test  P<0.05.
(TIF)
S4 Fig. Negative controls for PGK1 immunohistochemistry. (A) Positive staining for PGK1
in sectioned sciatic tissue. (B) Secondary only control for PGK1 staining in sectioned sciatic
tissue showed no fluorescent staining.
(TIF)
S5 Fig. GAPDH and PGK1 are co-expressed in the axons and growth cones of primary
motor neurons. (A) GAPDH and PGK1 are expressed in axons and growth cones of primary
MNs. Scale Bar = 15 μM.
(TIF)
S6 Fig. Protein levels of PGK1 in early and late symptomatic SPC. (A) PGK1 levels in con-
trol littermates and SMA p5 SPC, PGK1 was significantly reduced (10%) in the SPC of early-
symptomatic P5 SMA mice (B) PGK1 levels in control littermates and SMA late-symptomatic
P8 SPC, PGK1 was significantly reduced (20%) in the SPC of late-symptomatic SMA mice.
N = 6 per genotype. Bar chart (mean & s.e.m) Unpaired two-tailed student t-test  P<0.05,
 p<0.01.
(TIF)
S7 Fig. Increasing the concentration of injected pgk1 MO resulted in an increase in severe
motor neurons. Injection of 0.5mM resulted in a significant increase in severe motor neurons
compared to controls, with 0.75mM MO resulting in an even larger number of severe motor
neurons compared to controls. Bar chart (mean & s.e.m.). Unpaired two-tailed student t-test
 P<0.05,  p<0.01,  p<0.001,  p<0.0001.
(TIF)
S8 Fig. Treatment with terazosin does not cause any morphological or development defects
in zebrafish embryos. Representative bright field of images 28 hpf zebrafish treated with tera-
zosin. (A) Control untreated zebrafish. (B) Treatment of 2.5 μM Terazosin and (C) Treatment
of 5 μM Terazosin (TZ) from 6 hpf does not lead to any morphological or developmental delay
compared to untreated zebrafish.
(TIF)
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